纯能受体对手:高血压的补充治疗方法
Rocio Bautista-Pérez1, Martha Franco2
1Department of Molecular Biology, Instituto Nacional de Cardiología Ignacio Chávez, México City 14080, Mexico.
Pharmaceuticals (Basel, Switzerland)
|August 29, 2024
概括
纯能受体,通过高的间歇性腺三酸盐 (ATP) 激活,通过损害功能,导致高血压. 准这些受体可能为血压控制提供新的策略.
科学领域:
- 腎臟病學 (nephrology) 是一種醫學專業.
- 心血管生理学心血管生理学
- 药理学 药理学是指药理学的学科.
背景情况:
- 尽管有进展,但高血压仍然难以控制,导致诸如慢性病等心血管并发症.
- 改变功能是高血压患者的一个重大问题,需要新的治疗方法.
- 纯能信号越来越多地被认为是它在高血压病理生理学中的作用.
研究的目的:
- 审查纯能受体在高血压期间功能改变中的作用.
- 阐明纯能信号对高血压的发展和维持有所贡献的机制.
- 突出清能受体与其他系统之间的相互作用,如氨酸 - 血管新生系统,在功能障碍.
主要方法:
- 文献综述侧重于纯能受体在功能和高血压中的参与.
- 分析研究研究了间歇性腺三酸盐 (ATP) 对机制的影响.
- 检查纯能信号,血管活性物质和损伤之间的相互作用.
主要成果:
- 升高的间歇性ATP激活脏纯能受体,这是高血压的关键途径.
- 高水平的ATP会扰乱压力自然注射,球过率,脏血流自调和管状球反.
- 由ATP引起的变化导致分泌量下降,血管活性物质的释放,功能下降和管间损伤.
- 血管新素II和纯能受体之间的有害相互作用加剧了功能障碍.
结论:
- 由ATP升高激活纯能受体是高血压相关功能障碍的一个关键因素.
- 脏纯能信号的调节失调会损害血压平衡所必需的机制.
- 准纯能受体是改善血压控制和预防心血管并发症的潜在策略.
相关概念视频
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
160
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
160
01:23Antihypertensive Drugs: Vasodilators
492
Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
492
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
142
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
142
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
147
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
147
01:22Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers
559
α-Adrenergic antagonists, known as α-blockers, exert their effects by inhibiting α-adrenoceptors, leading to specific physiological actions. α1-blockers and α2-blockers have distinct pharmacological actions and therapeutic applications.
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally,...
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally,...
559
01:30Antihypertensive Drugs: Angiotensin II Receptor Blockers
614
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
614